Federico Corelli is professor of medicinal chemistry at the University of Siena, Italy. He graduated in Chemistry and Pharmaceutical Technology at the University of Rome La Sapienza in 1977 under the supervision of Professor R. Giuliano, then he joined Professor M. Artico's group at the same University in 1980 and was appointed assistant professor in 1983. In 1987 he moved as associate professor of medicinal chemistry to the University of Siena, where he was appointed full professor since July 1st, 2000.
He was the Dean of the Faculty of Pharmacy since November 2003 to October 2009, served as the Chairman for two cycles of the PhD School in Pharmaceutical Sciences of the University of Siena and in 2007 was appointed in the Scientific Committee of the PhD School in Science of Drugs and Bioactive Substances of the University of Pisa.
He was in the scientific/organizing board of twenty national and international scientific conferences. In 2008-2012, he was the director of the Workshop in Synthetic Metodologies in Medicinal Chemistry of the Division of Medicinal Chemistry of the Italian Chemical Society. Since January 1st, 2013 is a member of the Steering Committee of the Division of Medicinal Chemistry of the Italian Chemical Society.
He acts as a reviewer for a number of international scientific journals. He is the author of 10 patent applications, more than 200 scientific papers, 8 chapters in books, and delivered a number of lectures in international and national meetings. He has also been editor of a book. His research interests include the synthesis of biologically active compounds, especially antiviral, antibacterial and antifungal compounds, CNS and antitumor agents. His current research activity mainly deals with the discovery of new selective ligands of cannabinoid receptors and allosteric modulators of GABAB receptor and investigations of the involvement of these receptors in different CNS diseases. Among his main recent achievements can be mentioned the discovery of several potent and selective cannabinoid type 2 (CB2) receptor agonists/inverse agonists, novel GABAB positive allosteric modulators (PAMs), the first small-molecule TRPV1 ligands.